NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line ...
Bristol-Myers Squibb (BMS) has been steadily building its position in fibrotic diseases for some time, but accelerated its efforts this week with a $1.25 billion deal giving it the right to buy ...
announced its preprint article titled “Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology ...